Press Releases

Date Title and Summary Additional Formats
Toggle Summary New National Survey Reveals 82 Percent of Postmenopausal Women Miss Critical Connection Between Osteoporosis and Bone Fractures
Joint Survey from National Osteoporosis Foundation, HealthyWomen and Radius Health Sounds an Urgent Call to Action for Women to Know Their Risk, Get the Facts ‘Fractured Truth' Education Campaign Addresses Entrenched Misperceptions, Asks Women to Rethink Their Beliefs About Bone Health WALTHAM,
View HTML
Toggle Summary Pivotal Phase III trial of abaloparatide-SC in Japanese women and men with osteoporosis achieves primary endpoint
Radius partner Teijin Pharma has submitted a New Drug Application  for abaloparatide-SC for treatment of osteoporosis in Japan   WALTHAM, Mass. , May 27, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today announced that its partner, Teijin Pharma Limited
View HTML
Toggle Summary Radius Announces Appointment of Michael Franken as Senior Vice President and Chief Business Officer
Radius Announces Appointment of Michael Franken as Senior Vice President and Chief Business Officer CAMBRIDGE, Mass., April  20, 2011—   Radius Health, Inc., a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health
View HTML
Toggle Summary Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study View HTML
Toggle Summary Radius Announces European Medicines Agency Validates Marketing Authorization Application for Abaloparatide-SC for the Treatment of Osteoporosis in Postmenopausal Women
Radius Initiates Human Pharmacokinetic Study of Optimized Transdermal Patch of Investigational Drug Abaloparatide WALTHAM, Mass., Dec. 04, 2015 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS), today announced that the European Medicines Agency (EMA) has validated for review the Marketing
View HTML
Toggle Summary Radius Announces FDA Acceptance for Filing of New Drug Application for Abaloparatide-SC for the Treatment of Postmenopausal Women with Osteoporosis
WALTHAM, Mass., May 31, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that its New Drug Application (NDA)
View HTML
Toggle Summary Radius Announces Follow-Up on the Positive Phase 3 Top-Line Results for Its Investigational Drug Abaloparatide-SC in Postmenopausal Women With Severe Osteoporosis
Radius Announces Follow-Up on the Positive Phase 3 Top-Line Results for Its Investigational Drug Abaloparatide-SC in Postmenopausal Women With Severe Osteoporosis WALTHAM, Mass., Jan. 12, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. ( RDUS ) today announced a series of follow-ups on the positive
View HTML
Toggle Summary Radius Announces Key Changes to Management Team
Radius Appoints John Yates as Chief Medical Officer, Greg Williams as Chief Development Officer, and Promotes Gary Hattersley to Chief Scientific Officer
View HTML
Toggle Summary Radius Announces Positive Phase 3 Top-Line Results for Its Investigational Drug Abaloparatide-SC in Postmenopausal Women With Severe Osteoporosis
Study Meets Primary Endpoint of Reducing the Percentage of Patients with Incident Vertebral Fracture and Also Meets Important Secondary Endpoints: Adverse Events Consistent with Previous Clinical Experience Radius Remains on Track for Completion of the Ongoing 6-Month ACTIVExtend Study and NDA
View HTML
Toggle Summary Radius Announces Positive Phase 3 Topline Results for TYMLOS® (abaloparatide) Subcutaneous Injection in Males with Osteoporosis
ATOM study met the primary endpoint of change in lumbar spine bone mineral density at 12 months (p-value
View HTML